Some data presented a few weeks ago at the annual meeting of the European Association for Urology appear to have surprised not only the study’s authors, but pretty much everyone else as well. … READ MORE …
Filed under: Uncategorized | Tagged: low risk, replacement, serum, surgery, testosterone, TRT | 6 Comments »
Conventional wisdom (dating back to the 1940s) has long been that giving testosterone supplements to men who had been treated for prostate cancer is a really bad idea. … READ MORE …
Filed under: Uncategorized | Tagged: hypogonadal, replacement, serum, testosterone, TRT | 4 Comments »
For many years now, there have been subsets of specialists and patients who have argued that the “standard” serum testosterone level of 50 ng/dl, used by regulatory authorities and others as a measure indicating a castrate level of serum testosterone, is too high. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castrate, dhydrotestosterone, estosterone, level, serum | 18 Comments »
Discussions about the pros and cons of testosterone replacement therapy (TRT) in relation to (a) stimulating risk for prostate cancer in men who have not been diagnosed and (b) recurrence of prostate cancer among men who have been diagnosed and treated often aren’t entirely clear about a very key factor. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: hypogonadism, replacement, risk, serum, testosterone, TRT | 18 Comments »
For the past 40 years, the formal level of “effectiveness” of androgen deprivation therapy (ADT, also known as “hormone” therapy) for men treated for high-risk, progressive, and/or metastatic prostate cancer has been a serum testosterone level of < 50 ng/dl (equivalent to < 1.7 nmol/l). However, … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, deprivation, serum, testosterone | 7 Comments »
A new report from a group of Italian researchers has suggested that circulating serum testosterone (T) levels in the blood may be a risk for upgrading and upstaging among men initially diagnosed with low-risk prostate cancer who are managed on active surveillance. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: active, risk, serum, surveillance, testosterone | 1 Comment »
Over the years there have been multiple debates about whether different types of androgen deprivation therapy (ADT) really do or don’t extend the survival of men with advanced prostate cancer of differing types and whether the degree to which ADT initially suppresses serum testosterone levels affects that survival. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, deprivation, hormone, serum, testosterone | 48 Comments »
We had “missed” a poster presented at the recent meeting of the European Urology Association that appears to “put to bed” — in a positive fashion — the question of a relationship between nadir serum testosterone (T) levels in men on continuous androgen deprivation therapy (ADT) and the long-term effectiveness of continuous ADT. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, continuous, deprivation, outcome, serum, T, testosterone | 1 Comment »
For many years, the formal threshold level of serum testosterone (T) used to define medical “castration” has been < 50 ng/dl. However, it is widely recognized that this level is probably not low enough to accurately define a medically castrate state. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: medical castration, serum, testosterone, threshold | 3 Comments »
We don’t want to suggest that the recent paper by a Japanese research team in the journal Andrology is necessarily going to revolutionize the diagnosis of clinically significant prostate cancer. A great deal more work would be required to justify the hypothesis that they put forward. On the other hand, their hypothesis is definitely interesting. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: androgen, chromatography, deprivation, dihydrotestosterone, mass spectrometry, PSA, risk, serum, testosterone, tissue | 9 Comments »
A paper just published in Clinical Cancer Research has suggested that — at least for one immunotherapeutic agent (“vaccine”) in development for the treatment of advanced prostate cancer — it may be possible to define a subgroup of men who are more likely to respond well to treatment than others. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antibody, glycan, microarray, PROSTVAC-VF, serum | 4 Comments »
As many readers of this news service will be aware, good data on the recovery of libido and sexual function after a period of androgen deprivation therapy (ADT) are limited. We have long known that such recovery is variable, and we also know that it can take time, but sound data from a large cohort of patients has been “missing in action,” so to speak. A new paper by Ng et al. has now remedied this problem. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, function, libido, masculinity, potency, serum, sex, testosterone | 4 Comments »
An article in the June issue of the Canadian Urological Association Journal offers preliminary evidence from a randomized clinical trial that men treated for 6 months with a short-acting LHRH agonist may recover normal serum testosterone (T) levels faster than those treated for the same time with a long-acting LHRH agonist. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: LHRH agonist, long-acting, recovery, serum, short-acting, testosterone | 2 Comments »
An article in the May issue of BJU International has proposed establishment of an international data registry as being “the quickest way” to establish basic data on the risks related to testosterone replacement therapy in men with untreated prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: hypogonadism, risk, serum, T, testosterone | Leave a comment »
